Prostate Cancer – Landscape & Forecast – Disease Landscape & Forecast
Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Next-generation hormonal treatments have expanded beyond metastatic castrate-resistant prostate cancer (mCRPC), dominating current treatment of nonmetastatic CRPC and hormone-sensitive prostate cancer (HSPC). The continued uptake of hormonal therapies, plus the expected label expansions of targeted agents (e.g., Janssen / GlaxoSmithKline’s Akeega, Pfizer’s Talzenna, Novartis’ Pluvicto) and anticipated approvals of emerging therapies (e.g., POINT Biopharma’s 177Lu-PNT2002 and Exelixis / Genentech’s Cabometyx + Tecentriq), will drive robust market growth over the 2022-2032 forecast period.
QUESTIONS ANSWERED
- What is the estimated size of the clinically and commercially relevant drug-treatable prostate cancer populations, and how will drug-treatment rates vary by geography, setting, and over time?
- How will the prostate cancer market evolve over the 10-year forecast period? What are their drivers and constraints?
- What are the interviewed experts’ insights on the current treatment options for prostate cancer?
- How will the adoption and anticipated label expansions of biomarker-driven therapies, such as PARP inhibitors and PSMA-targeted radioligands, reshape the prostate cancer treatment landscape?
- What is the clinical and commercial potential of emerging regimens, like Cabometyx plus Tecentriq and 177Lu-PNT2002? How are they likely to be positioned in the market?
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
KEY FEATURES
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Prostate Cancer - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Key Updates
- Market Outlook
- Key findings
- Major-market share of prostate cancer drug classes: 2022
- Major-market share of prostate cancer drug classes: 2032
- Drug-treatable population share and major-market sales share: 2022
- Drug-treatable population share and major-market sales share: 2032
- Population positioning of therapies in prostate cancer
- Prostate cancer SWOT analysis
- Market drivers and constraints
- Segment-specific trends
- Key findings
- Forecast
- Etiology and Pathophysiology
- Disease overview
- Disease pathophysiology
- Biology and metastatic spread of prostate cancer
- Development of castrate-resistant prostate cancer
- Molecular alterations involved in castrate-resistant prostate cancer
- Prostate-specific antigen
- Key clinical uses of prostate-specific antigen as a biomarker in prostate cancer
- Staging classification and grading systems for prostate cancer
- TNM staging classification system for prostate cancer
- Classification of level of risk of recurrence of prostate cancer
- Key pathways and drug targets
- Anatomic location and architecture of the prostate gland
- Disease overview
- Epidemiology
- Current Treatment
- Key findings
- Treatment goals
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for prostate cancer
- Current treatments used for prostate cancer
- Market events impacting the use of key current therapies for prostate cancer
- Hormonal agents
- PSMA-targeted radioligands
- Immunotherapies
- Bone metastases-targeted agents
- Cytotoxic agents
- PARP inhibitors
- PARP inhibitors / hormonal agents
- Medical practice
- Newly diagnosed low- and intermediate-risk hormone-sensitive prostate cancer
- Newly diagnosed high-risk and N1M0 hormone-sensitive prostate cancer
- Metastatic hormone-sensitive prostate cancer
- Biochemically recurrent prostate cancer
- Nonmetastatic castrate-resistant prostate cancer
- First-line metastatic castrate-resistant prostate cancer
- Second- and subsequent-line metastatic castrate-resistant prostate cancer
- Patient characteristics influencing drug selection in prostate cancer
- Region-specific treatment practices
- Key findings
- Unmet Need Overview
- Drug Pipeline
- Emerging Therapies
- Key findings
- Key emerging therapies
- Key therapies in development for prostate cancer
- Estimated market authorization dates of key emerging therapies for the treatment of prostate cancer
- Immunotherapies
- Kinase inhibitors
- PSMA-targeted radioligands
- Angiogenesis inhibitors + Immune checkpoint inhibitors
- CDK4/6 inhibitors
- Antibody-drug conjugates
- PARP inhibitors
- Hormonal agents
- CYP11A1 inhibitors
- Early-phase pipeline analysis
- Key findings
- Access and reimbursement overview
- Methodology
- Appendix
Saurabh Virdi, B.Tech., Lead Healthcare Research & Data Analyst, Oncology. Mr. Virdi has more than seven years working in the pharmaceutical industry providing analytical support in various therapy areas, including oncology, HIV, vaccines, specialty pharma, and rare diseases. Prior to joining Clarivate, he was an assistant project manager at DelveInsight Business Research LLP, where he was responsible for developing and delivering customized market and asset value forecasts. Before DelveInsight, he worked at WNS GSK Knowledge center and SmartAnalyst, where, as part of multifunctional teams, he helped clients’ decision making throughout the development journey from early-stage to marketed drugs. He obtained his bachelor’s degree in biotechnology from Delhi Technological University in India.
Narendra Parihar, B.D.S., M.P.H., Senior Manager, Epidemiology. Dr Parihar is a team lead at Clarivate Epidemiology. He specializes in modelling and forecasting epidemiology patient populations across multiple indications. His primary areas of interest are cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer. His qualifications include a master’s degree in public health with specialization in health policy, economics, and finance from Tata Institute of Social Sciences Mumbai, and a bachelor’s degree in dental surgery from the Rajasthan University of Health Sciences.